Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (19344)	7/13/1998 11:46:00 AM
From: ACAN	Read Replies (1) \| Respond to of 79281

Doug; ANRG is this chart developing its attitude. Recent news Home - Yahoo! - Help Question: What should you expect from your online service? [ Business \| US Market \| By Industry \| IPO \| AP \| S&P \| International \| PRNews \| BizWire ] Wednesday July 8, 9:41 am Eastern Time Company Press Release SOURCE: GHLstockalert 'Will Test Results Of New Arthritis Drug Cause Stock Price Of Anergen Inc. To Explode?' Asks GHLstockalert OCALA, Fla., July 8 /PRNewswire/ -- Anergen Inc. (Nasdaq: ANRG - news) was chosen today by GHLstockalert as ''the most likely small-cap, bio-tech company whose stock is a timebomb that could literally explode in price in the immediate future.'' Commenting on this prediction, a spokesperson for GHLstockalert said, ''If you want to make huge profits, you must solve a huge problem. Which is exactly what Anergen may be on the verge of doing as it begins clinical trials of its new arthritis drug candidate. ''The market is huge. Arthritis is second only to heart disease as a cause of work disability. It already results in 39 million doctor visits each year and the number of people with arthritis is set to explode as the leading edge of the baby boomer generation enters the prime years of the disease. ''Approximately 40 million Americans already suffer from arthritis and that number is expected to grow to 59.4 million according to a recent report issued jointly by the National Institute of Health, the Center for Disease Control and Prevention (CDC), the Arthritis Foundation and the American College of Rheumatology. More than 100 different diseases affecting the joints are classified as arthritis and the stiffness and pain can often dramatically impede an individual's ability to function. ''Nobody can predict with precision the outcome of a clinical trial, but Anergen's state-of-the-art biotechnology research looks extremely promising. ''So much so, in fact, Anergen is now teamed up with N.V. Organon, one of the pharmaceutical business units of Akzo Nobel headquartered in The Netherlands. Akzo Nobel is a market-driven and technology based company that employs 70,000 people and is active in more than 60 countries with consolidated sales of 24.1 billion. ''In our judgment, collaboration between Akzo Nobel, with its enormous marketing and distribution network, and Anergen, with its team of dedicated scientists and feverish pace of research, are the exact ingredients that can create a possible explosion in the share price of this tiny but progressive bio-tech company.'' Is there any reason not to invest in this company? Yes. According to GHLstockalert, ''We could be wrong.'' NOTE: GHLstockalert has no personal or business affiliation whatsoever with Anergen Inc. (Nasdaq: ANRG - news) or any other publicly traded company. SOURCE: GHLstockalert More Quotes and News: Anergen Inc (Nasdaq:ANRG - news) Related News Categories: biotech, medical/pharmaceutical Help Copyright c 1998 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information. Questions or Comments? Thanks, Allan